BR0010823A - Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular - Google Patents

Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular

Info

Publication number
BR0010823A
BR0010823A BR0010823-5A BR0010823A BR0010823A BR 0010823 A BR0010823 A BR 0010823A BR 0010823 A BR0010823 A BR 0010823A BR 0010823 A BR0010823 A BR 0010823A
Authority
BR
Brazil
Prior art keywords
sba
immune response
cellular immune
humoral
enhance
Prior art date
Application number
BR0010823-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of BR0010823A publication Critical patent/BR0010823A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR0010823-5A 1999-05-20 2000-05-19 Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular BR0010823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (de) 1999-05-20 2000-05-19 Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort

Publications (1)

Publication Number Publication Date
BR0010823A true BR0010823A (pt) 2002-03-05

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010823-5A BR0010823A (pt) 1999-05-20 2000-05-19 Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular

Country Status (11)

Country Link
EP (1) EP1183045A2 (es)
JP (1) JP2003500365A (es)
KR (1) KR20020012221A (es)
AU (2) AU5214200A (es)
BR (1) BR0010823A (es)
CA (1) CA2373239A1 (es)
DE (1) DE10024788A1 (es)
MX (1) MXPA01011660A (es)
TR (1) TR200103333T2 (es)
WO (2) WO2000071154A2 (es)
ZA (1) ZA200109147B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020012221A (ko) * 1999-05-20 2002-02-15 파르마솔 게엠베하 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
EP1675869B1 (en) * 2003-10-23 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Stabilised compositions
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
KR101557502B1 (ko) 2005-09-14 2015-10-06 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를기반으로 하는 약물 제제의 방법
AU2007216966C1 (en) 2006-02-22 2014-03-20 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20180079458A (ko) 2009-06-12 2018-07-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20180318415A1 (en) * 2015-12-08 2018-11-08 Glaxosmithkline Biologicals, Sa Novel adjuvant formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
JP2002521423A (ja) * 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
KR20020012221A (ko) * 1999-05-20 2002-02-15 파르마솔 게엠베하 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트

Also Published As

Publication number Publication date
KR20020012221A (ko) 2002-02-15
WO2000071154A3 (de) 2001-06-28
AU5214200A (en) 2000-12-12
MXPA01011660A (es) 2004-04-05
AU5809100A (en) 2000-12-12
ZA200109147B (en) 2002-05-08
CA2373239A1 (en) 2000-11-30
DE10024788A1 (de) 2000-11-23
TR200103333T2 (tr) 2002-04-22
EP1183045A2 (de) 2002-03-06
JP2003500365A (ja) 2003-01-07
WO2000071077A2 (en) 2000-11-30
WO2000071154A2 (de) 2000-11-30

Similar Documents

Publication Publication Date Title
BR0010823A (pt) Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular
Masson et al. Calcium phosphate: a substitute for aluminum adjuvants?
ATE229978T1 (de) Helicobacter proteine und impstoffe
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
DE69840962D1 (de) Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
HU9904549A (en) Vaccines
ATE264691T1 (de) Newcastle-krankheitsvirus-kombinationsimpfstoff
PT1135166E (pt) Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina
DK1140165T3 (da) Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
DE69939747D1 (de) Verfahren von dna-impfung
ITFI920052A1 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
DK0686030T3 (da) Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler
DE69828182D1 (de) Polynukleotid-impfstoff-formulierungen
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE109004T1 (de) Toleranzinduktion gegenüber einem fremdantigen.
BR0207020A (pt) Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.